BRPI0414254A - composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulação - Google Patents
composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulaçãoInfo
- Publication number
- BRPI0414254A BRPI0414254A BRPI0414254-3A BRPI0414254A BRPI0414254A BR PI0414254 A BRPI0414254 A BR PI0414254A BR PI0414254 A BRPI0414254 A BR PI0414254A BR PI0414254 A BRPI0414254 A BR PI0414254A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- disease
- formulation
- treating
- manufacturing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000004090 dissolution Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 abstract 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA FABRICAR UMA COMPOSIçãO FARMACêUTICA, PARA O TRATAMENTO DE PELO MENOS UMA DOENçA E PARA CONTROLAR A TAXA DE DISSOLUçãO DE UMA FORMULAçãO". A presente invenção diz respeito a uma composição farmacêutica que compreende uma quantidade terapeuticamente eficaz de um composto ativo receptor de cálcio e pelo menos um excipiente farmaceuticamente aceitável, em que a composição tem um perfil de dissolução controlado. A presente invenção ainda diz respeito a um método para fabricar a composição farmacêutica, bem como um método de tratar uma doença usando a composição farmacêutica.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122018013029-6A BR122018013029B1 (pt) | 2003-09-12 | 2004-09-10 | Método para fabricar uma composição farmacêutica |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50221903P | 2003-09-12 | 2003-09-12 | |
| US60/502,219 | 2003-09-12 | ||
| PCT/US2004/026732 WO2005034928A1 (en) | 2003-09-12 | 2004-09-10 | Rapid dissolution formulation of a calcium receptor-active compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0414254A true BRPI0414254A (pt) | 2006-11-07 |
| BRPI0414254B1 BRPI0414254B1 (pt) | 2021-03-02 |
| BRPI0414254B8 BRPI0414254B8 (pt) | 2021-05-25 |
Family
ID=34434844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414254A BRPI0414254B8 (pt) | 2003-09-12 | 2004-09-10 | composição farmacêutica compreendendo hcl de cinacalceto |
| BR122018013029-6A BR122018013029B1 (pt) | 2003-09-12 | 2004-09-10 | Método para fabricar uma composição farmacêutica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122018013029-6A BR122018013029B1 (pt) | 2003-09-12 | 2004-09-10 | Método para fabricar uma composição farmacêutica |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US7829595B2 (pt) |
| EP (8) | EP2316442A1 (pt) |
| JP (3) | JP5026077B2 (pt) |
| KR (1) | KR101332058B1 (pt) |
| CN (1) | CN1946382B (pt) |
| AR (1) | AR045637A1 (pt) |
| AU (1) | AU2004279318C1 (pt) |
| BR (2) | BRPI0414254B8 (pt) |
| CA (1) | CA2536487C (pt) |
| CY (5) | CY1119609T1 (pt) |
| DE (1) | DE19164145T1 (pt) |
| DK (6) | DK2821067T3 (pt) |
| EA (1) | EA013425B1 (pt) |
| ES (7) | ES2735216T3 (pt) |
| HR (1) | HRP20130114T4 (pt) |
| HU (5) | HUE043958T2 (pt) |
| IL (1) | IL173737A (pt) |
| IS (1) | IS3027B (pt) |
| MX (1) | MXPA06002616A (pt) |
| MY (1) | MY142046A (pt) |
| NO (1) | NO335739B1 (pt) |
| NZ (1) | NZ545498A (pt) |
| PL (6) | PL3260117T3 (pt) |
| PT (6) | PT2821067T (pt) |
| SG (1) | SG146608A1 (pt) |
| SI (6) | SI3395339T1 (pt) |
| TR (4) | TR201910180T4 (pt) |
| TW (1) | TWI344363B (pt) |
| WO (1) | WO2005034928A1 (pt) |
| ZA (1) | ZA200602710B (pt) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100074949A1 (en) * | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| TWI344363B (en) * | 2003-09-12 | 2011-07-01 | Amgen Inc | Rapid dissolution formulation of a calcium receptor-active compound |
| DK2502911T3 (en) | 2004-06-24 | 2017-06-06 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| ES2332016T3 (es) * | 2005-05-16 | 2010-01-22 | Teva Pharmaceutical Industries Ltd. | Procedimiento para la preparacion de hidrocloruro de cinacalcet. |
| EP1805135A2 (en) * | 2005-05-23 | 2007-07-11 | Teva Pharmaceutical Industries Ltd. | Purification of cinacalcet |
| MX2007000982A (es) * | 2005-05-23 | 2007-04-16 | Teva Pharma | Clorhidrato de cinacalcet amorfo y preparacion del mismo. |
| US8729085B2 (en) | 2005-05-26 | 2014-05-20 | Dainippon Sumitomo Pharma Co., Ltd. | Pharmaceutical composition |
| JP5244597B2 (ja) * | 2005-09-02 | 2013-07-24 | アムジエン・インコーポレーテツド | カルシリティック化合物またはカルシウム模倣性化合物を用いて腸液バランスを調節する方法 |
| CA2625299A1 (en) * | 2005-11-22 | 2007-05-31 | Teva Pharmaceutical Industries Ltd. | Crystal forms of cinacalcet hci and processes for their preparation |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| DK1993559T3 (en) | 2006-02-03 | 2016-10-03 | Opko Renal Llc | Treatment of vitamin D deficiency and MALFUNCTION with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US8415501B2 (en) * | 2006-03-23 | 2013-04-09 | Amgen, Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
| US7393967B2 (en) * | 2006-04-27 | 2008-07-01 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of cinacalcet base |
| DE602007003067D1 (de) * | 2006-04-27 | 2009-12-17 | Teva Pharma | Verfahren zur herstellung einer cinacalcetbase |
| SI2679228T1 (en) | 2006-06-21 | 2018-06-29 | Opko Ireland Global Holdings, Ltd. | THERAPY WITH THE USE OF VITAMIN D ADDITIONAL FIBER AND HORMON RESISTANCE OF VITAMIN D |
| US20090258949A1 (en) * | 2006-06-27 | 2009-10-15 | Johannes Ludescher | Amorphous form of cinacalcet |
| BRPI0715635A2 (pt) * | 2006-09-01 | 2013-07-02 | Teva Pharma | compàsitos sàlidos de um composto de cÁlcio receptor-ativo |
| US20080146845A1 (en) * | 2006-11-20 | 2008-06-19 | Boaz Gome | Process for preparing Cinacalcet |
| WO2008064202A2 (en) * | 2006-11-20 | 2008-05-29 | Dr. Reddy's Labortories, Ltd. | Modified-release formulations of calcium receptor-active compounds |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| WO2008122010A1 (en) * | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals, Inc. | Pharmaceutical calcimimetics |
| SI2148661T1 (sl) | 2007-04-25 | 2013-04-30 | Cytochroma Inc. | Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti naosilec |
| DK2148684T3 (da) | 2007-04-25 | 2013-04-22 | Cytochroma Inc | Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens |
| CA2691196C (en) | 2007-06-21 | 2016-05-24 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
| WO2009025792A2 (en) * | 2007-08-16 | 2009-02-26 | Teva Pharmaceutical Industries Ltd. | Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof |
| US20090275780A1 (en) * | 2008-05-05 | 2009-11-05 | Medichem, S.A. | Process for controlling the particle size of a 3-(trifluoromethyl)phenyl]-1-aminopropane derivative |
| US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20120009258A1 (en) * | 2008-09-25 | 2012-01-12 | Ratiopharm Gmbh | Compacted cinacalcet |
| WO2010086129A1 (en) | 2009-01-27 | 2010-08-05 | Rathiopharm Gmbh | Inclusion complex comprising cinacalcet and cyclodextrin |
| RU2543714C2 (ru) | 2009-03-20 | 2015-03-10 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза |
| CA2762137A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| WO2010136035A2 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| EP2314286A1 (de) | 2009-10-21 | 2011-04-27 | Ratiopharm GmbH | Schmelzgranuliertes Cinacalcet |
| RS60087B1 (sr) | 2010-03-29 | 2020-05-29 | Opko Ireland Global Holdings Ltd | Postupci i kompozicije za snižavanje nivoa paratireoidnog hormona |
| CN109745313A (zh) | 2010-08-11 | 2019-05-14 | 德雷克塞尔大学 | 治疗帕金森病中运动障碍的d3多巴胺受体激动剂 |
| PT2642980T (pt) * | 2010-11-23 | 2020-06-24 | Amgen Inc | Formulação pediátrica |
| US20130261132A1 (en) | 2010-11-26 | 2013-10-03 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| US20130267516A1 (en) | 2010-11-26 | 2013-10-10 | Leo Pharma A/S | Substituted cyclopentyl-azines as casr-active compounds |
| US20130245084A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| WO2012069420A2 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| SG11201403367YA (en) | 2011-12-19 | 2014-07-30 | Amgen Inc | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| EP2804588B1 (en) | 2012-01-17 | 2017-09-06 | Zentiva Saglik Urunleri San. Ve Tic. A.S. | Method for producing cinacalcet compositions for direct tableting |
| BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
| CN102885792A (zh) * | 2012-10-12 | 2013-01-23 | 华润赛科药业有限责任公司 | 盐酸西那卡塞的口服固体速释制剂 |
| ES2547577T3 (es) | 2012-11-09 | 2015-10-07 | K.H.S. Pharma Holding Gmbh | Formulaciones de liberación inmediata de cinacalcet |
| CN113842362A (zh) | 2012-11-14 | 2021-12-28 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| ES2737756T3 (es) * | 2012-12-21 | 2020-01-15 | Synthon Bv | Composición de comprimido que comprende clorhidrato de cinacalcet |
| SG10201706148WA (en) | 2013-02-01 | 2017-08-30 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| WO2014207691A1 (en) | 2013-06-26 | 2014-12-31 | Jubilant Life Sciences Limited | Disintegrant free composition of cinacalcet |
| WO2015136329A1 (en) * | 2014-03-14 | 2015-09-17 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical composition of cinacalcet |
| WO2015150944A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof |
| US10220047B2 (en) * | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| CN104721164B (zh) * | 2015-03-25 | 2017-07-07 | 河北仁合益康药业有限公司 | 一种盐酸西那卡塞薄膜衣片组合物 |
| US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
| CA3019508A1 (en) | 2016-03-31 | 2017-10-05 | Intercept Pharmaceuticals, Inc. | Oral preparation having exceptional elutability |
| US11331283B2 (en) * | 2017-08-16 | 2022-05-17 | Unichem Laboratories Ltd | Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders |
| EP3773533A1 (en) | 2018-03-30 | 2021-02-17 | FTF Pharma Private Limited | Liquid dosage forms of cinacalcet or salt thereof |
| US10920483B2 (en) | 2018-10-25 | 2021-02-16 | Mark Mutchnik | Window seal for preventing water penetration |
| RU2750761C2 (ru) * | 2019-09-17 | 2021-07-02 | Общество с ограниченной ответственностью "АМЕДАРТ" | Ядро таблетки, содержащей цинакальцета гидрохлорид |
| IL295986A (en) * | 2020-02-29 | 2022-10-01 | Kempharm Inc | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
| CN112546010A (zh) * | 2020-12-02 | 2021-03-26 | 普莱赛思(天津)生命科技有限公司 | 一种肾病药物组合物及其制备方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517179A (en) | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
| IL88150A0 (en) | 1987-11-02 | 1989-06-30 | Merck & Co Inc | Pharmaceutical tablet compositions containing phthalizine acetic acid compounds |
| EP0357815A1 (de) | 1988-09-06 | 1990-03-14 | Siemens Aktiengesellschaft | Schaltbare Konstantstromquelle mit I2L-Gattern |
| AU4664889A (en) | 1988-11-30 | 1990-06-26 | Schering Corporation | Sustained release diltiazem formulation |
| NZ231897A (en) * | 1988-12-30 | 1992-09-25 | Monsanto Co | Dry water-soluble granular composition comprising glyphosate and a liquid surfactant |
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US4931286A (en) | 1989-04-19 | 1990-06-05 | Aqualon Company | High gloss cellulose tablet coating |
| DD299322A5 (de) * | 1989-09-21 | 1992-04-09 | Maschinenfabrik Rieter Ag,Ch | Verfahren und vorrichtung zur feinreinigung von textilfasern |
| US5011068A (en) * | 1989-12-05 | 1991-04-30 | Progressive Tool & Industries Co. | Automotive body framing system |
| ATE264292T1 (de) | 1991-08-23 | 2004-04-15 | Nps Pharma Inc | Kalzium - receptor aktive arylalkylamine |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| ES2256370T3 (es) | 1991-08-23 | 2006-07-16 | Nps Pharmaceuticals, Inc. | Moleculas activas para el receptor de calcio. |
| US6313146B1 (en) * | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| WO1994018959A1 (en) | 1993-02-23 | 1994-09-01 | Brigham And Women's Hospital, Inc. | Calcium receptor-active molecules |
| US6210714B1 (en) * | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
| UA41909C2 (uk) * | 1994-07-22 | 2001-10-15 | Елі Ліллі Енд Компані | Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат |
| EP1275635A1 (en) * | 1994-10-21 | 2003-01-15 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
| GB9424766D0 (en) | 1994-12-07 | 1995-02-08 | Wellcome Found | Pharmaceutical composition |
| GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| DE19530575A1 (de) | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz |
| DE69722934T2 (de) * | 1996-05-01 | 2004-05-27 | NPS Pharmaceuticals, Inc., Salt Lake City | Verbindungen , die auf anorganische ionen-rezeptoren wirken |
| US5837292A (en) | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
| WO1998001417A1 (fr) | 1996-07-08 | 1998-01-15 | Kirin Beer Kabushiki Kaisha | Composes actifs comme recepteurs du calcium |
| DE19637082A1 (de) | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
| TW483881B (en) | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
| IE970588A1 (en) * | 1997-08-01 | 2000-08-23 | Elan Corp Plc | Controlled release pharmaceutical compositions containing tiagabine |
| WO1999009458A1 (de) | 1997-08-13 | 1999-02-25 | OCé PRINTING SYSTEMS GMBH | Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern |
| ATE219658T1 (de) | 1998-03-06 | 2002-07-15 | Eurand Int | Schnell zerfallende tablette |
| US6525084B2 (en) | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
| WO2000021910A2 (en) * | 1998-10-14 | 2000-04-20 | Ortho-Mcneil Pharmaceutical, Inc. | 1,2-disubstituted cyclopropanes |
| NZ511850A (en) * | 1998-11-23 | 2003-11-28 | Monsanto Co | Highly concentrated aqueous glyphosate compositions |
| UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6447809B1 (en) * | 1999-05-11 | 2002-09-10 | Metagenics, Inc. | Composition for promoting healthy bone structure |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| FR2800735B1 (fr) | 1999-11-09 | 2002-02-01 | Centre Nat Rech Scient | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation |
| PL355391A1 (en) * | 1999-12-22 | 2004-04-19 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| WO2001078725A2 (en) * | 2000-04-13 | 2001-10-25 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
| US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| US6656492B2 (en) * | 2000-06-30 | 2003-12-02 | Yamanouchi Pharmaceutical Co., Ltd. | Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
| CA2423329A1 (en) | 2000-09-22 | 2003-03-20 | Takeda Chemical Industries, Ltd. | Solid preparations |
| JP2002167327A (ja) * | 2000-09-22 | 2002-06-11 | Takeda Chem Ind Ltd | 固形製剤 |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| IN191028B (pt) * | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
| EP1401503B1 (en) | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer |
| EP1321142A1 (en) | 2001-12-21 | 2003-06-25 | Novartis AG | Solid pharmaceutical composition for oral administration of Tegaserod |
| AU2003238670A1 (en) | 2002-04-05 | 2003-10-27 | Cadila Healthcare Limited | Fast disintegrating oral dosage forms |
| US20050147670A1 (en) * | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
| WO2004030669A1 (en) | 2002-09-30 | 2004-04-15 | Schering Corporation | Use of tricyclic amides for the treatment of disorders of calcium homeostasis |
| GB0230015D0 (en) | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
| TWI344363B (en) | 2003-09-12 | 2011-07-01 | Amgen Inc | Rapid dissolution formulation of a calcium receptor-active compound |
| DE602005025977D1 (de) | 2004-08-23 | 2011-03-03 | Teva Pharma | Kristalline form des ibandronat-natriums und herstellungsverfahren dafür |
| NL1028867C2 (nl) | 2005-04-26 | 2006-10-27 | Xycarb Ceramics B V | Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting. |
| US8922209B2 (en) | 2008-03-11 | 2014-12-30 | The University Of Western Ontario | System and method for magnetic resonance imaging |
-
2004
- 2004-09-10 TW TW093127508A patent/TWI344363B/zh not_active IP Right Cessation
- 2004-09-10 ES ES18175497T patent/ES2735216T3/es not_active Expired - Lifetime
- 2004-09-10 TR TR2019/10180T patent/TR201910180T4/tr unknown
- 2004-09-10 EP EP10014567A patent/EP2316442A1/en not_active Withdrawn
- 2004-09-10 DK DK14163366.9T patent/DK2821067T3/en active
- 2004-09-10 EP EP18175495.3A patent/EP3395338B1/en not_active Revoked
- 2004-09-10 ES ES18175495T patent/ES2737348T3/es not_active Expired - Lifetime
- 2004-09-10 PL PL17185704T patent/PL3260117T3/pl unknown
- 2004-09-10 DK DK17185704.8T patent/DK3260117T3/da active
- 2004-09-10 TR TR2019/09267T patent/TR201909267T4/tr unknown
- 2004-09-10 PT PT141633669T patent/PT2821067T/pt unknown
- 2004-09-10 HU HUE17185704A patent/HUE043958T2/hu unknown
- 2004-09-10 PL PL18175499T patent/PL3395340T3/pl unknown
- 2004-09-10 EP EP18175499.5A patent/EP3395340B8/en not_active Revoked
- 2004-09-10 SI SI200432473T patent/SI3395339T1/sl unknown
- 2004-09-10 BR BRPI0414254A patent/BRPI0414254B8/pt active IP Right Grant
- 2004-09-10 ES ES17185704T patent/ES2734057T3/es not_active Expired - Lifetime
- 2004-09-10 PT PT18175495T patent/PT3395338T/pt unknown
- 2004-09-10 CN CN2004800327959A patent/CN1946382B/zh not_active Expired - Lifetime
- 2004-09-10 EP EP14163366.9A patent/EP2821067B1/en not_active Expired - Lifetime
- 2004-09-10 JP JP2006526096A patent/JP5026077B2/ja not_active Expired - Lifetime
- 2004-09-10 DK DK18175497.9T patent/DK3395339T3/da active
- 2004-09-10 CA CA2536487A patent/CA2536487C/en not_active Expired - Lifetime
- 2004-09-10 EP EP17185704.8A patent/EP3260117B8/en not_active Revoked
- 2004-09-10 EP EP19164145.5A patent/EP3578175B1/en not_active Revoked
- 2004-09-10 SI SI200432475T patent/SI3395338T1/sl unknown
- 2004-09-10 PL PL14163366T patent/PL2821067T3/pl unknown
- 2004-09-10 HU HUE18175495 patent/HUE044279T2/hu unknown
- 2004-09-10 BR BR122018013029-6A patent/BR122018013029B1/pt active IP Right Grant
- 2004-09-10 AR ARP040103266A patent/AR045637A1/es unknown
- 2004-09-10 HU HUE18175497A patent/HUE045411T2/hu unknown
- 2004-09-10 MY MYPI20043684A patent/MY142046A/en unknown
- 2004-09-10 ES ES14163366.9T patent/ES2655435T3/es not_active Expired - Lifetime
- 2004-09-10 PT PT47814298T patent/PT1663182E/pt unknown
- 2004-09-10 AU AU2004279318A patent/AU2004279318C1/en not_active Expired
- 2004-09-10 US US10/937,870 patent/US7829595B2/en active Active
- 2004-09-10 SI SI200432416T patent/SI2821067T1/en unknown
- 2004-09-10 TR TR2019/10177T patent/TR201910177T4/tr unknown
- 2004-09-10 WO PCT/US2004/026732 patent/WO2005034928A1/en active Application Filing
- 2004-09-10 NZ NZ545498A patent/NZ545498A/en not_active IP Right Cessation
- 2004-09-10 PL PL18175495T patent/PL3395338T3/pl unknown
- 2004-09-10 DK DK04781429.8T patent/DK1663182T4/da active
- 2004-09-10 HU HUE14163366A patent/HUE035596T2/en unknown
- 2004-09-10 SI SI200432472T patent/SI3260117T1/sl unknown
- 2004-09-10 HU HUE18175499 patent/HUE044822T2/hu unknown
- 2004-09-10 SI SI200432018T patent/SI1663182T2/sl unknown
- 2004-09-10 PT PT18175497T patent/PT3395339T/pt unknown
- 2004-09-10 MX MXPA06002616A patent/MXPA06002616A/es active IP Right Grant
- 2004-09-10 ES ES04781429T patent/ES2401769T5/es not_active Expired - Lifetime
- 2004-09-10 EP EP04781429.8A patent/EP1663182B2/en not_active Expired - Lifetime
- 2004-09-10 ES ES18175499T patent/ES2735226T3/es not_active Expired - Lifetime
- 2004-09-10 EA EA200600566A patent/EA013425B1/ru unknown
- 2004-09-10 DK DK18175499.5T patent/DK3395340T3/da active
- 2004-09-10 PT PT17185704T patent/PT3260117T/pt unknown
- 2004-09-10 SI SI200432474T patent/SI3395340T1/sl unknown
- 2004-09-10 PT PT18175499T patent/PT3395340T/pt unknown
- 2004-09-10 EP EP18175497.9A patent/EP3395339B8/en not_active Revoked
- 2004-09-10 PL PL18175497T patent/PL3395339T3/pl unknown
- 2004-09-10 ES ES19164145T patent/ES2812198T1/es active Pending
- 2004-09-10 DK DK18175495.3T patent/DK3395338T3/da active
- 2004-09-10 DE DE19164145.5T patent/DE19164145T1/de active Pending
- 2004-09-10 TR TR2019/10447T patent/TR201910447T4/tr unknown
- 2004-09-10 PL PL04781429T patent/PL1663182T5/pl unknown
- 2004-09-10 SG SG200806469-3A patent/SG146608A1/en unknown
- 2004-09-10 KR KR1020067003448A patent/KR101332058B1/ko not_active Expired - Lifetime
-
2006
- 2006-02-14 IL IL173737A patent/IL173737A/en active IP Right Grant
- 2006-02-23 IS IS8324A patent/IS3027B/is unknown
- 2006-04-03 ZA ZA200602710A patent/ZA200602710B/en unknown
- 2006-04-11 NO NO20061640A patent/NO335739B1/no unknown
-
2010
- 2010-11-09 US US12/942,646 patent/US9375405B2/en active Active
-
2012
- 2012-05-14 JP JP2012110758A patent/JP5849015B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-08 HR HRP20130114TT patent/HRP20130114T4/hr unknown
-
2014
- 2014-08-15 JP JP2014165378A patent/JP5940120B2/ja not_active Expired - Lifetime
-
2016
- 2016-05-24 US US15/163,356 patent/US20160338975A1/en not_active Abandoned
-
2017
- 2017-11-20 CY CY20171101211T patent/CY1119609T1/el unknown
-
2018
- 2018-04-30 US US15/966,812 patent/US20180243238A1/en not_active Abandoned
- 2018-12-20 US US16/227,882 patent/US20190117592A1/en not_active Abandoned
-
2019
- 2019-06-28 CY CY20191100682T patent/CY1122259T1/el unknown
- 2019-07-10 CY CY20191100735T patent/CY1121814T1/el unknown
- 2019-07-10 CY CY20191100734T patent/CY1121812T1/el unknown
- 2019-07-18 CY CY20191100767T patent/CY1121820T1/el unknown
-
2020
- 2020-03-27 US US16/832,087 patent/US20200222340A1/en not_active Abandoned
- 2020-11-06 US US17/091,798 patent/US20210052518A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0414254A (pt) | composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulação | |
| ATE542534T1 (de) | Methode zur schmerzbekämpfung | |
| BRPI0508561A (pt) | 3-'4-heterociclil-1,2,3-triazol-1-il-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crÈnicas | |
| BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| PT2172450E (pt) | Novo derivado sulfonamida de ácido malónico e sua utilização farmacêutica | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| TW200639159A (en) | Treatment of pain | |
| BRPI0417376A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização | |
| AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
| AR047993A1 (es) | Composicion farmaceutica que comprende pimobendano | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
| BR0308133A (pt) | Forma polimórfica cristalina de cloridrato de irinotecan | |
| BR0315462A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação | |
| DE60215313D1 (de) | Indolderivate und deren verwendung als gnrh antagonisten | |
| BRPI0507120A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização | |
| WO2005115432A3 (en) | Treatment of ocular diseases and disorders using lantibiotic compositions | |
| BRPI0517032A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| MA27157A1 (fr) | Methode de traitement d'affections osseuses. | |
| PH12022552807A1 (en) | Novel compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2h-chromen-2-on-7-yl sulphate and use thereof | |
| RU2007138266A (ru) | Комбинация ингибитора стероидсульфатазы и аскомицина | |
| CY1113703T1 (el) | Ταχειας διαλυσης φαρμακοτεχνικη μορφη της σινακαλσετης hci | |
| BRPI0507985A (pt) | derivados de piperazina uréia para o tratamento de endometriose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B15N | Others concerning applications: notification of judicial decision |
Free format text: INPI-52400.210725/2017-51 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO 25A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO 0214721-08.2017.4.02.5101 AUTOR: AMGEN INC. REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI DECISAO: EMENTA - MANDADO DE SEGURANCA IMPETRADO COM A FINALIDADE DE EXIGIR QUE A AUTORIDADE IMPETRADA INICIE, NO PRAZO DE 60 (SESSENTA) DIAS, O EXAME DE MERITO DA PATENTE PI 0414254-3, COM DEPOSITO EFETUADO VIA PCT HA MAIS DE MAIS DE TREZE ANOS.RECONHECIMENTO DE DEMORA EXCESSIVA E DESARRAZOADA DO INPI PARA PRATICAR O ATO, CARACTERIZANDO VIOLACAO DOS ARTIGOS 5O, XXXIII, DA CF, E 48 E 49, DA LEI 9.784/99.APELACAO DESPROVIDA. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B15N | Others concerning applications: notification of judicial decision |
Free format text: INPI-52400.210725/2017-51 SECAO: 25A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0214721-08.2017.4.02.5101 APELANTE: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI APELADO: AMGEN INC DECISAO: O TRANSITO EM JULGADO DO ACORDAO CONFIRMANDO SENTENCA DESFAVORAVEL AO INPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B15V | Prolongation of time limit allowed |